Viewpoints

 
 
  • Micromets 'No Biggie' in Early-Stage Breast Cancer Dr Lidia Schapira reports on an analysis that indicates axillary micrometastases and low-volume disease should not be used to guide systemic treatment in early breast cancer.
  • Big Benefits From Goserelin in Young Breast Cancer Patients The GnRH agonist goserelin preserved fertility and improved pregnancy and survival in ER-positive breast cancer patients receiving chemotherapy in a study discussed by Dr Lidia Schapira.
  • Tamoxifen Prevents Breast Cancer: Worth a Chat Dr Lidia Schapira reports on the published findings of the IBIS-I study, which confirm that tamoxifen prevents breast cancer in patients at increased risk. Isn't it time to have a chat with patients?
  • Second-line Oxaliplatin Benefits Pancreatic Cancer Patients Dr Alok Khorana reports on the CONKO study, which shows that patients with pancreatic cancer who receive gemcitabine in first-line therapy benefit from second-line oxaliplatin-based therapy.
  • SOFT Already Informing Choices in HR+ Breast Cancer The SOFT results, published in December, are informing clinical decisions in young women with early HR+ breast cancer, says Dr Lidia Schapira, especially those at high risk for recurrence.
  • Does SBRT Revolutionize Metastatic NSCLC? Dr Jack West argues that an encouraging new study of stereotactic body radiation therapy should not necessarily change practice.
  • Breast Cancer 2014: SOFT Proves Year's Best Dr Lidia Schapira reviews the year in breast cancer, highlighting inroads made in the individualization of care, unprecedented survival data, and the practice-changing results of the SOFT trial.
  • CMS Proviso on Lung Cancer Screening: Good or Bad? Potential barriers or appropriate guardrails? Dr Jack West comments on the recent CMS decision to cover lung cancer screening -- provided that certain conditions are met.
  • Oncology's Unrecognized Crisis Why should 71% of young oncologists in Europe report burnout? Dr Susana Banerjee, author of a much touted European survey, explains her study findings and critical issues that need to be addressed.
  • Why Are Young Oncologists Burned Out? Tim Moynihan, MD, coauthor of a landmark study on burnout in US oncology fellows, talks about the stressors that are wearing down oncologists before their careers begin.
  • BOLERO-2: OS Is So-So, but So What? Dr Lidia Schapira reports on the overall survival data from BOLERO-2 and questions whether overall survival is a valid endpoint in studies of targeted therapy in metastatic breast cancer.
  • Should PIK3CA Inform Therapy Choice in Breast Cancer? Dr Lidia Schapira reports on a study showing that PIK3CA mutations may indicate trastuzumab resistance in HER2+ breast cancer but cautions use of the biomarker as a basis for clinical decisions.
  • Got Colon Cancer, Get Milk? Dr Alok Khorana reports on a study indicating that increased milk and calcium intake is associated with improved outcomes after diagnosis of colorectal cancer.
  • Decoding Breast Cancer Risk: BRCA and Beyond Dr Lidia Schapira talks with Dr Leif Ellisen about the controversy of widespread BRCA testing and the practical issues in assessing a woman's risk of developing breast and ovarian cancer.
  • Mandatory Extended RAS Testing for mCRC Dr Alok Khorana discusses a meta-analysis that lends support for extended RAS testing to identify patients with advanced colorectal cancer who should not receive EGFR inhibitors.
  • pCR and Improved Survival in Breast Cancer? Dr. Lidia Schapira discusses an analysis of NeoALTTO, which indicates that achieving pCR after neoadjuvant therapy for HER2+ cancer is associated with improved outcomes -- for some more than others.
  • Who Needs Zoledronic Acid in Early Breast Cancer? Dr. Lidia Schapira describes the role of adjuvant bisphosphonates in early breast cancer as unclear, but suggests that host factors may prove key to efficacy.
  • Best Timing of Chemo in Rectal Cancer Unclear Dr. Alok Khorana reports that EORTC 22921 confirms that local control is improved with chemotherapy, but says other trials are needed to confirm whether neoadjuvant or adjuvant is superior.
  • Why Breast Cancer Patients Should Be Big Losers Dr. Lidia Schapira reports on a large meta-analysis confirming that obesity negatively affects risk for mortality in breast cancer patients -- and what both patients and doctors should do about it.
  • Let the Sun Shine: Vitamin D in CRC Dr. Alok Khorana reports on a recent study indicating that vitamin D may increase survival in patients with colorectal cancer.